Accelerated partial breast irradiation in early stage breast cancer

Paulina E. Galavis; Camille Hardy Abeloos; Pine C. Cheng; Christine Hitchen; Allison McCarthy; Juhi M. Purswani; Bhartesh Shah; Sameer Taneja; Naamit K. Gerber

doi:10.3389/fonc.2022.1049704

Accelerated partial breast irradiation in early stage breast cancer

Paulina E. Galavis, Camille Hardy Abeloos, Pine C. Cheng, Christine Hitchen, Allison McCarthy, Juhi M. Purswani, Bhartesh Shah, Sameer Taneja, Naamit K. Gerber

Biomedical Engineering

Research output: Contribution to journal › Review article › peer-review

Abstract

Accelerated partial breast irradiation (APBI) is increasingly used to treat select patients with early stage breast cancer. However, radiation technique, dose and fractionation as well as eligibility criteria differ between studies. This has led to controversy surrounding appropriate patients for APBI and an assessment of the toxicity and cosmetic outcomes of APBI as compared to whole breast irradiation (WBI). This paper reviews existing data for APBI, APBI delivery at our institution, and ongoing research to better define patient selection, treatment delivery, dosimetric considerations and toxicity outcomes.

Original language	English (US)
Article number	1049704
Journal	Frontiers in Oncology
Volume	12
DOIs	https://doi.org/10.3389/fonc.2022.1049704
State	Published - Nov 10 2022

Keywords

accelerated partial breast irradiation
dosimetric considerations
early stage breast cancer
toxicity outcomes
treatment planning

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.3389/fonc.2022.1049704

Cite this

@article{61d539e53d74435c8257a69bbaf58078,

title = "Accelerated partial breast irradiation in early stage breast cancer",

abstract = "Accelerated partial breast irradiation (APBI) is increasingly used to treat select patients with early stage breast cancer. However, radiation technique, dose and fractionation as well as eligibility criteria differ between studies. This has led to controversy surrounding appropriate patients for APBI and an assessment of the toxicity and cosmetic outcomes of APBI as compared to whole breast irradiation (WBI). This paper reviews existing data for APBI, APBI delivery at our institution, and ongoing research to better define patient selection, treatment delivery, dosimetric considerations and toxicity outcomes.",

keywords = "accelerated partial breast irradiation, dosimetric considerations, early stage breast cancer, toxicity outcomes, treatment planning",

author = "Galavis, {Paulina E.} and Abeloos, {Camille Hardy} and Cheng, {Pine C.} and Christine Hitchen and Allison McCarthy and Purswani, {Juhi M.} and Bhartesh Shah and Sameer Taneja and Gerber, {Naamit K.}",

note = "Publisher Copyright: Copyright {\textcopyright} 2022 Galavis, Abeloos, Cheng, Hitchen, McCarthy, Purswani, Shah, Taneja and Gerber.",

year = "2022",

month = nov,

day = "10",

doi = "10.3389/fonc.2022.1049704",

language = "English (US)",

volume = "12",

journal = "Frontiers in Oncology",

issn = "2234-943X",

publisher = "Frontiers Media SA",

}

TY - JOUR

T1 - Accelerated partial breast irradiation in early stage breast cancer

AU - Galavis, Paulina E.

AU - Abeloos, Camille Hardy

AU - Cheng, Pine C.

AU - Hitchen, Christine

AU - McCarthy, Allison

AU - Purswani, Juhi M.

AU - Shah, Bhartesh

AU - Taneja, Sameer

AU - Gerber, Naamit K.

PY - 2022/11/10

Y1 - 2022/11/10

N2 - Accelerated partial breast irradiation (APBI) is increasingly used to treat select patients with early stage breast cancer. However, radiation technique, dose and fractionation as well as eligibility criteria differ between studies. This has led to controversy surrounding appropriate patients for APBI and an assessment of the toxicity and cosmetic outcomes of APBI as compared to whole breast irradiation (WBI). This paper reviews existing data for APBI, APBI delivery at our institution, and ongoing research to better define patient selection, treatment delivery, dosimetric considerations and toxicity outcomes.

AB - Accelerated partial breast irradiation (APBI) is increasingly used to treat select patients with early stage breast cancer. However, radiation technique, dose and fractionation as well as eligibility criteria differ between studies. This has led to controversy surrounding appropriate patients for APBI and an assessment of the toxicity and cosmetic outcomes of APBI as compared to whole breast irradiation (WBI). This paper reviews existing data for APBI, APBI delivery at our institution, and ongoing research to better define patient selection, treatment delivery, dosimetric considerations and toxicity outcomes.

KW - accelerated partial breast irradiation

KW - dosimetric considerations

KW - early stage breast cancer

KW - toxicity outcomes

KW - treatment planning

UR - http://www.scopus.com/inward/record.url?scp=85142472104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85142472104&partnerID=8YFLogxK

U2 - 10.3389/fonc.2022.1049704

DO - 10.3389/fonc.2022.1049704

M3 - Review article

AN - SCOPUS:85142472104

SN - 2234-943X

VL - 12

JO - Frontiers in Oncology

JF - Frontiers in Oncology

M1 - 1049704

ER -

Accelerated partial breast irradiation in early stage breast cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this